Form 4: Ionis Pharma EVP Sells Shares Under 10b5-1 Plan

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer Shannon L. Devers, sold 3,977 shares of common stock for approximately $81.34 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Shannon L. Devers, Executive Vice President and Chief Human Resources Officer of Ionis Pharmaceuticals Inc. (IONS), reported a sale of common stock.
• A total of 3,977 shares of common stock were disposed of on January 22, 2026.
• The shares were sold at a weighted average price of $81.3403, with individual transactions ranging from $81.33 to $81.37.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Devers on September 3, 2024.
• Following this transaction, Ms. Devers directly beneficially owns 22,541 shares of common stock.

Sentiment

Score: 5

Explanation: A Form 4 filing for a pre-planned insider stock sale is a routine disclosure and generally neutral in sentiment, as it reflects a pre-scheduled event rather than a reaction to new company performance or news.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the sale of shares by a key executive, which is a routine disclosure under a pre-arranged trading plan and does not necessarily indicate a change in company fundamentals or executive confidence.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Shannon L. Devers, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation